Greiner Bio-One North America, Inc.  

4238 Capital Drive
Monroe,  NC  28110

United States
https://www.gbo.com

• Booth: 2023

Greiner Bio-One North America, Inc., is a privately held manufacturing company that specializes in the development, production and distribution of high-quality plastic laboratory products for the medical and research fields. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. The Preanalytics division develops and produces innovative collection systems for human and veterinary blood, urine and saliva samples; the Bioscience division develops and produces specialized products for the cultivation of cell cultures, microplates for high-throughput screening, biobanking solutions, and more. As an international manufacturer with presence in more than 100 countries, Greiner Bio-One provides manufacturing, distribution logistics and product application support to the world’s largest health organizations and pharmaceutical and biotechnology corporations. Learn more at www.gbo.com.

 Press Releases

• Ilke Panzer Appointed New Greiner Bio-One Division Manager (Apr 26, 2024)
  • Ilke Panzer (57) will succeed Manfred Stanek as CEO of Greiner Bio-One on February 1, 2024. Stanek had been the interim head of the medical technology division
  • Panzer has international experience in the healthcare and pharmaceutical sectors and many years of management expertise
  • One of main goals of the designated CEO is continuing global growth, chiefly on the US market

  
  Vienna/Kremsmünster, December 6, 2023 – Ilke Panzer will take over as head of Greiner Bio-One, Greiner’s medical technology division, with effect from February 1, 2024. She succeeds Manfred Stanek, who has been the interim head of the division since September 1, 2023, and who will return in full to his role as Chief Operating Officer (COO) of the holding company Greiner AG after the handover.
  
  “We are delighted to have Ilke Panzer on board as our division manager. We were convinced by her im-pressive career at major US companies such as General Electric and Johnson & Johnson. She has considerable international sector experience but is also familiar with European culture. A real win for Greiner Bio-One!” said Axel Kühner, CEO of Greiner AG.
  
  “Ilke Panzer combines solid industry expertise with an international vision and a focus on innovation. Her understanding of leadership and her values make her an excellent fit at Greiner. Thanks to her extensive management experience, she can continue to drive the success of our medical technology division,” said Manfred Stanek, COO of Greiner AG and interim CEO of Greiner Bio-One.
  
  “I am delighted by the trust placed in me and look forward to returning to Europe, both in my professional and in my private life. Greiner Bio-One successfully combines its international focus with its regional roots as a family company. My goal is to leverage the potential of Greiner Bio-One and make a significant contribution to sustainable growth,” said Ilke Panzer.
  
  Ilke Panzer (57) was born in Germany but pursued her career in the US, where most recently she worked as a freelance healthcare innovation consultant. With management experience at Assurance Laboratories LLC, BloodCenter of Wisconsin, and Johnson & Johnson, she has excellent knowledge of the healthcare and pharmaceutical industries. She began her career at General Electric, with roles including general manager for Global Ultrasound. Panzer holds degrees in Engineering, Computer and Systems Engineering from the University of Connecticut and from the National Technological University in Fort Collins, Colorado. She has been a member of the Supervisory Board at the German pharmaceutical and laboratory equipment supplier Sartorius AG since 2017.
  
  Ilke Panzer was born in Münster (Germany) and has lived in the US since her university studies She is married and will be based in Austria.
  
  ++++
  Greiner Bio-One International GmbH
  
  Greiner Bio-One specializes in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilization. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors.
  
  In 2022, Greiner Bio-One International GmbH generated a turnover of 693 million euros and had 2,794 employees, 29 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).
  
  ++++
  
  Further information from:
  Julia Franke / Expert Global Communication
  PHONE: +43 7583 6791-1133
  E-MAIL: Julia.franke@gbo.com

• Ana-Maria Šimundić becomes Director of Global Medical & Clinical Affairs (Apr 26, 2024)
  On 1 December 2023, Ana-Maria Šimundić took up the newly created position as Director of Global Medical & Clinical Affairs at Greiner Bio-One. In this role, she heads the Global Medical & Clinical Affairs department and will represent Greiner Bio-One in national and international professional circles as well as foster exchange with experts in science and the field. Her area of responsibility includes all medical and clinical topics, such as research studies or studies related to product approvals.
  
  Kremsmünster, December 2023 – The leading medical device manufacturer Greiner Bio-One, with headquarters in Kremsmünster (Austria), is expanding its positioning in the Preanalytics business area. The newly created Global Medical & Clinical Affairs department will assume an important interface function. This encompasses supporting development, clinical testing of new and existing products, conducting clinical trials and taking responsibility for the approval of products in order to further improve the safety and effectiveness of the products. Further tasks include close cooperation with healthcare institutions, physicians and medical opinion leaders, as well as product training for healthcare professionals.
   

  “We are very pleased to have won Ana-Maria Šimundić as Director of the newly created Global Medical & Clinical Affairs department. With her on board, we now have one of the world's leading experts from the field of preanalytics in our team. She is the ideal choice for us to ensure that we can continue to offer innovative and efficient solutions that will help our customers overcome the daily challenges in the preanalytical laboratory environment.”
  - Stefan Gebauer, Head of Business Unit Preanalytics

  
  Broad expertise
  
  Ana-Maria Šimundić is a well-known key opinion leader in Europe in the sector laboratory diagnostics and preanalytics. She not only brings a wealth of expertise and experience in the medical and clinical field, but is also very well networked. From 2020 to 2021, she was President of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and now she is a member of the International Federation of Clinical Chemistry (IFCC) Executive Board as an EFLM representative and a former President of the EFLM board. During her time as EFLM President, she set up the EFLM Preanalytics Conference and led various working groups, for example. Most recently, she was Managing Director of Clinical Hospital Sveti Duh in Zagreb and Department Head of Medical Laboratory Diagnostics.
  
  Ana-Maria Šimundić completed her doctorate in 2003 at the Faculty of Pharmacy and Biochemistry of the University of Zagreb, where she is a university professor for laboratory medicine. She has received multiple awards for her research in the areas of preanalytics and quality management.
  
  ++++
  
  Greiner Bio-One International GmbH
  
  Greiner Bio-One specializes in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilization. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors.
  
  In 2022, Greiner Bio-One International GmbH generated a turnover of 693 million euros and had 2,794 employees, 29 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).
  
  ++++
  
  Further information from:
  Julia Franke / Expert Global Communication
  PHONE: +43 7583 6791-1133
  E-MAIL: Julia.franke@gbo.com
   

• Greiner Awarded EcoVadis Gold Rating (Apr 26, 2024)
  • The Greiner Group as a whole has received the internationally recognized EcoVadis sustainability rating for the first time.
  • The Kremsmünster-based plastics company was rated in the top 5% in its sector. 
  • Greiner performed best in the environment category and aims to improve further and receive a platinum status. 

  
  Kremsmünster/Vienna, October 24, 2023 - Individual divisions at Greiner have already been rated by EcoVadis, the world’s largest provider of corporate sustainability ratings, in recent years. This year marked the first time the Group as a whole was rated, i.e. including the Greiner Packaging, Greiner Bio-One and NEVEON divisions. Greiner scored 73 out of 100 points, giving it gold status. Performance is grouped into four themes: environment, labor and human rights, ethics and sustainable procurement. Greiner came top in the environment category, scoring 80 points.
  
  Sustainability ratings increasingly important both to customers and to suppliers 
  
  Fewer emissions and less waste: Sustainability and protecting the environment have always been at the heart of Greiner’s activities. Sustainability now also plays a role in corporate finance. Back in October 2022, Greiner placed a promissory note loan with an interest rate tied to sustainability performance. 
  
  “Sustainability plays a key role for us, for our customers and on the financial market. In connection with our sustainable promissory note loan, we therefore set ourselves the goal of working only with suppliers who have an EcoVadis rating of at least 50 points by 2030,” said Hannes Moser, CFO at Greiner. 
  
  EcoVadis has been rating the Greiner Packaging division since 2014 and Greiner Bio-One since 2022. “While we are very happy with the result of this first Group-wide rating, we are certainly not going to get complacent,” commented Sabine Schellander, co-head of Sustainability. “We want to keep improv-ing. The EcoVadis rating shows us what the next steps are. Our goal is to be in the top 1% and receive a platinum status.”
  
  Sustainability efforts affect the entire value chain 
  Efforts to improve sustainability do not stop at the company gates. Greiner is taking further steps to make supply chains more transparent. Only if supplier emissions are reduced can its own Scope 3 emis-sions be reduced, i.e. greenhouse gas emissions throughout the company’s upstream and downstream value chain. 
   
  About EcoVadis
  The EcoVadis rating covers a broad range of non-financial management systems including environmental, labor and human rights, ethics and sustainable procurement impacts. These are evaluated by international experts and adjusted to account for the sector, country and size of the company. www.ecovadis.com 
  
  About Greiner
  Based in Kremsmünster, Austria, Greiner is a world-leading plastics and foam solutions company. With the three operating divisions Greiner Packaging, NEVEON and Greiner Bio-One, the company is at home in all manner of industrial sectors. Established in 1868, the Group is now one of the leading foam producers and plastics processors for the packaging, furniture, sports and automotive industries as well as medical technology and the pharmaceutical sector. In fiscal 2022, Greiner generated turnover of EUR 2.33 billion and had over 11,600 employees at 120 locations in 34 countries. The Executive Board consists of CEO Axel Kühner, CFO Hannes Moser and COO Manfred Stanek. www.greiner.com 
  
  ++++
  
  Inquiries
  Gerti Wallner
  Media Spokesperson Greiner AG 
  Mobile: +43 664 8859 8617
  E-mail: gerti.wallner@greiner.com
   

• Greiner Bio-One launches new urine cup on the market (Apr 26, 2024)
  The Urine Cup with Integrated Transfer Device provides safe and hygienic urine collection for your daily routine.
  
  Kremsmünster, October 2022 – The Urine Cup with Integrated Transfer Device allows you to collect and transport urine samples safely to the requested destination. Thanks to the integrated transfer device, sample transfer from the cup to an evacuated tube is simple, fast and hygienic.
  
  Increased safety
  The optimized threading of the Urine Cup makes it easy to open and close. In addition, a stabilizing flange makes the cup more robust and prevents over-threading. The recessed transfer device integrated into the lid of the cup helps to reduce the risk of needlestick injuries to an absolute minimum. 
  
  New label design
  The perforated label acts as a sterility integrity seal visually indicating at a glance if the product has been opened prior to use.
  
  Designed with the environment in mind
  The sterility of the cup is maintained by the label seal instead of an individual blister pack per cup, saving on 1.7 million metres of plastic film compared to previous product versions (based on 10 million cups). This is a significant step toward reduction of unnecessary plastic packaging.
  
  Line of urine collection products
  
  Since urine samples are a potentially infectious sample material, the closed, sterile VACUETTE® urine collection system makes a decisive contribution to hygienic working practices. The system consists of high-quality components which help to ensure efficiency in test procedures. In addition to sample tubes and beakers, the product line also includes individual kits of urine transfer devices and tubes for more convenience, as well as other accessories.
  
  For more information on the products of the VACUETTE® urine line, please visit our website www.gbo.com.
  
  
  ++++
  
  Greiner Bio-One International GmbH
  
  Greiner Bio-One specializes in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilization. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors.
   
  In 2021, Greiner Bio-One International GmbH generated a turnover of 695 million euros and had 2,540 employees, 28 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).
  
  
  ++++
  
  Further information from:
  Peter Föttinger, Head of Corporate Marketing
  PHONE:    +43 7583 6791-1150
  E-MAIL:    peter.foettinger@gbo.com